Table 1 Patients’ demographics and clinical characteristics
From: Objective measurement in routine care of people with Parkinson’s disease improves outcomes
All participantsa | Controlled | Uncontrolled (n = 80) | ||
|---|---|---|---|---|
(N = 103) | (N = 23) | Treatable (N = 67) | Contraindicated (N = 13) | |
Age | 74 (69–78) | 74 (68–78) | 74 (68–77) | 77 (71–80) |
Disease duration | 5 (3–10) | 4 (1–5) | 6 (4–11) | 8 (4–12) |
H&Y | 2 (2–3) | 2 (1–3) | 2 (2–3) | 3 (2–4) |
UPDRS I | 11 (8–16) | 11 (6–18) | 10 (8–16) | 13 (10–26) |
UPDRS II | 11 (7–17) | 8 (4–12) | 11 (9–17) | 22 (17–30) |
UPDRS III | 40 (31–51) | 31 (23–40) | 41 (32–50) | 54 (47–62) |
UPDRS IV | 3 (0–5) | 2 (0–4) | 3 (0–5) | 4 (0–5) |
UPDRS total | 65 (50–85) | 51 (37–67.2) | 65.5 (54–83.2) | 94.5 (81.5–109) |
LED | 650 (425–975) | 500 (375–715) | 700 (450–1075) | 700 (600–987) |
PDQ39 | 33 (17–51) | 23 (7–39) | 31 (18–50) | 55 (39–89) |
NMS | 10 (8–13) | 9 (6–12) | 11 (8–14) | 12 (8–14) |
MOCA | 22 (19–25) | 22 (19–25) | 22 (20–26) | 18 (13–23) |
BKS | 26.2 (21.5–31.8) | 22 (20.5–24.6) | 26.7 (22–30.9) | 34.2 (31.8–39.4) |
PTO | 60.2 (35–82) | 35 (31–51.8) | 62.4 (42.6–82) | 92 (82–99.3) |
DKS | 1.6 (0.7–3.8) | 2.4 (1.2–4.9) | 1.6 (0.7–4.2) | 0.7 (0.2–1.1) |
FDS | 8.3 (6.6–10.7) | 9 (7–11) | 8.5 (6.6–11.7) | 7.2 (5.6–8.6) |
PTT | 2 (0.7–6.9) | 1.2 (0.6–6.9) | 3 (0.6–7) | 1.5 (1–5.2) |
PTI | 6.6 (3.3–13.2) | 4.3 (2.3–8.9) | 6 (3.3–11) | 17.1 (12.3–26) |
